Compare TARA & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TARA | FT |
|---|---|---|
| Founded | N/A | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.1M | 199.8M |
| IPO Year | 2014 | N/A |
| Metric | TARA | FT |
|---|---|---|
| Price | $3.97 | $7.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $24.40 | N/A |
| AVG Volume (30 Days) | ★ 464.4K | 29.5K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.85% |
| EPS Growth | ★ 38.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,948,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.97 | $7.79 |
| 52 Week High | $7.82 | $8.35 |
| Indicator | TARA | FT |
|---|---|---|
| Relative Strength Index (RSI) | 44.83 | 39.54 |
| Support Level | $3.69 | $7.93 |
| Resistance Level | $4.23 | $8.08 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 41.74 | 22.64 |
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.